146 related articles for article (PubMed ID: 17434155)
21. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
22. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
Koo DH; Ryu MH; Ryoo BY; Beck MY; Na YS; Shin JG; Lee SS; Kim EY; Kang YK
Cancer Chemother Pharmacol; 2015 Jan; 75(1):173-82. PubMed ID: 25417047
[TBL] [Abstract][Full Text] [Related]
23. Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease.
Cascorbi I; Flüh C; Remmler C; Haenisch S; Faltraco F; Grumbt M; Peters M; Brenn A; Thal DR; Warzok RW; Vogelgesang S
Pharmacogenomics; 2013 Apr; 14(5):485-94. PubMed ID: 23556446
[TBL] [Abstract][Full Text] [Related]
24. [Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
Sun ZW; Wang XC; Gao J; Li J; Li YY; Dang YZ; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):524-8. PubMed ID: 23801203
[TBL] [Abstract][Full Text] [Related]
25. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation.
Ueshima S; Hira D; Fujii R; Kimura Y; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Horie M; Terada T; Katsura T
Pharmacogenet Genomics; 2017 Sep; 27(9):329-336. PubMed ID: 28678049
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
Tamura M; Kondo M; Horio M; Ando M; Saito H; Yamamoto M; Horio Y; Hasegawa Y
Nagoya J Med Sci; 2012 Feb; 74(1-2):133-40. PubMed ID: 22515119
[TBL] [Abstract][Full Text] [Related]
27. Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.
Akasaka K; Kaburagi T; Yasuda S; Ohmori K; Abe K; Sagara H; Ueda Y; Nagao K; Imura J; Imai Y
Cancer Chemother Pharmacol; 2010 Sep; 66(4):691-8. PubMed ID: 20035425
[TBL] [Abstract][Full Text] [Related]
28. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.
Choi HY; Bae KS; Cho SH; Ghim JL; Choe S; Jung JA; Jin SJ; Kim HS; Lim HS
Pharmacogenet Genomics; 2015 Dec; 25(12):595-608. PubMed ID: 26367500
[TBL] [Abstract][Full Text] [Related]
29. Expression of MDR1, LRP, BCRP and Bcl-2 genes at diagnosis of childhood all: comparison with MRD status after induction therapy.
Fedasenka UU; Shman TV; Savitski VP; Belevcev MV
Exp Oncol; 2008 Sep; 30(3):248-52. PubMed ID: 18806751
[TBL] [Abstract][Full Text] [Related]
30. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters.
Choudhuri S; Klaassen CD
Int J Toxicol; 2006; 25(4):231-59. PubMed ID: 16815813
[TBL] [Abstract][Full Text] [Related]
31. A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis.
Campa D; Müller P; Edler L; Knoefel L; Barale R; Heussel CP; Thomas M; Canzian F; Risch A
Int J Cancer; 2012 Dec; 131(12):2920-8. PubMed ID: 22473764
[TBL] [Abstract][Full Text] [Related]
32. Expression and promoter methylation analysis of ATP-binding cassette genes in pancreatic cancer.
Chen M; Xue X; Wang F; An Y; Tang D; Xu Y; Wang H; Yuan Z; Gao W; Wei J; Zhang J; Miao Y
Oncol Rep; 2012 Jan; 27(1):265-9. PubMed ID: 21956451
[TBL] [Abstract][Full Text] [Related]
33. Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and inflammatory bowel disease and their effects on disease behavior: a case-control and meta-analysis study.
Onnie CM; Fisher SA; Pattni R; Sanderson J; Forbes A; Lewis CM; Mathew CG
Inflamm Bowel Dis; 2006 Apr; 12(4):263-71. PubMed ID: 16633048
[TBL] [Abstract][Full Text] [Related]
34. Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival.
Suvannasankha A; Minderman H; O'Loughlin KL; Nakanishi T; Ford LA; Greco WR; Wetzler M; Ross DD; Baer MR
Br J Haematol; 2004 Nov; 127(4):392-8. PubMed ID: 15521915
[TBL] [Abstract][Full Text] [Related]
35. Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein.
Stam RW; van den Heuvel-Eibrink MM; den Boer ML; Ebus ME; Janka-Schaub GE; Allen JD; Pieters R
Leukemia; 2004 Jan; 18(1):78-83. PubMed ID: 14574327
[TBL] [Abstract][Full Text] [Related]
36. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
37. Drug resistance associated properties of blasts subpopulations with different CD34 expression in childhood acute lymphoblastic leukemia (ALL).
Shman TV; Fedasenka UU; Savitski VP; Kustanovich AM; Aleinikova OV
Exp Oncol; 2011 Sep; 33(3):145-9. PubMed ID: 21956467
[TBL] [Abstract][Full Text] [Related]
38. mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia. Low expression levels associated with a higher risk of toxic death.
Cortez MA; Scrideli CA; Yunes JA; Valera ET; Toledo SR; Pavoni-Ferreira PC; Lee ML; Petrilli AS; Brandalise SR; Tone LG
Pediatr Blood Cancer; 2009 Dec; 53(6):996-1004. PubMed ID: 19672972
[TBL] [Abstract][Full Text] [Related]
39. Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population.
Østergaard M; Ernst A; Labouriau R; Dagiliené E; Krarup HB; Christensen M; Thorsgaard N; Jacobsen BA; Tage-Jensen U; Overvad K; Autrup H; Andersen V
Scand J Gastroenterol; 2009; 44(1):65-73. PubMed ID: 18819034
[TBL] [Abstract][Full Text] [Related]
40. Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers.
Akamine Y; Miura M; Sunagawa S; Kagaya H; Yasui-Furukori N; Uno T
Xenobiotica; 2010 Nov; 40(11):782-9. PubMed ID: 20839930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
